Details
Stereochemistry | ACHIRAL |
Molecular Formula | C32H41N9O4 |
Molecular Weight | 615.7258 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C1CCN(CC1)C(=O)C2=CC=C(NC(=O)NC3=CC=C(C=C3)C4=NC(=NC(=N4)N5CCOCC5)N6CCOCC6)C=C2
InChI
InChIKey=DWZAEMINVBZMHQ-UHFFFAOYSA-N
InChI=1S/C32H41N9O4/c1-38(2)27-11-13-39(14-12-27)29(42)24-5-9-26(10-6-24)34-32(43)33-25-7-3-23(4-8-25)28-35-30(40-15-19-44-20-16-40)37-31(36-28)41-17-21-45-22-18-41/h3-10,27H,11-22H2,1-2H3,(H2,33,34,43)
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/21325073Curator's Comment: Description was created based on several sources, including http://www.pharmacodia.com/yaodu/html/v1/chemicals/0d8f8313c83e69d101e8997d3065fbff.html https://www.ncbi.nlm.nih.gov/pubmed/22261591
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21325073
Curator's Comment: Description was created based on several sources, including http://www.pharmacodia.com/yaodu/html/v1/chemicals/0d8f8313c83e69d101e8997d3065fbff.html https://www.ncbi.nlm.nih.gov/pubmed/22261591
Gedatolisib (PF-05212384, PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ and mTOR, originally being developed by Wyeth. Upon intravenous administration, gedatolisib inhibits both PI3K and mTOR kinases, which may result in apoptosis and growth inhibition of cancer cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K. Significant antitumor efficacy and a favorable pharmacokinetic/safety profile justified clinical evaluation of Gedatolisib. Gedatolisb is in phase II clinical trials by Pfizer for the treatment of acute myeloid leukaemia. Gedatolisb is in phase I clinical trials for the treatment of solid tumours.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4005 |
0.4 nM [IC50] | ||
Target ID: CHEMBL3267 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20166697 |
5.4 nM [IC50] | ||
Target ID: CHEMBL2842 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20166697 |
1.6 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
319 mg 1 times / week multiple, intravenous Highest studied dose Dose: 319 mg, 1 times / week Route: intravenous Route: multiple Dose: 319 mg, 1 times / week Sources: Page: p.6, 17 |
unhealthy, ADULT n = 4 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 4 Sources: Page: p.6, 17 |
DLT: Mucosal inflammation, skin rash... Dose limiting toxicities: Mucosal inflammation (grade 3, 25%) Sources: Page: p.6, 17skin rash (grade 3, 25%) |
154 mg 1 times / week multiple, intravenous MTD Dose: 154 mg, 1 times / week Route: intravenous Route: multiple Dose: 154 mg, 1 times / week Sources: Page: p.6, 17 |
unhealthy, ADULT n = 42 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 42 Sources: Page: p.6, 17 |
DLT: Mucosal inflammation, AST increased... Dose limiting toxicities: Mucosal inflammation (grade 3, 2.4%) Sources: Page: p.6, 17AST increased (2.4%) ALT increased (2.4%) |
222 mg 1 times / week multiple, intravenous Studied dose Dose: 222 mg, 1 times / week Route: intravenous Route: multiple Dose: 222 mg, 1 times / week Sources: Page: p.6, 17 |
unhealthy, ADULT n = 7 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 7 Sources: Page: p.6, 17 |
DLT: Mucosal inflammation... Other AEs: ALT increased, Mucosal inflammation... Dose limiting toxicities: Mucosal inflammation (grade 3, 42.9%) Other AEs:ALT increased (grade 2, 14.3%) Sources: Page: p.6, 17Mucosal inflammation (grade 3, 14.3%) Inflammation of mout (grade 3, 14.3%) |
266 mg 1 times / week multiple, intravenous Studied dose Dose: 266 mg, 1 times / week Route: intravenous Route: multiple Dose: 266 mg, 1 times / week Sources: Page: p.6, 17 |
unhealthy, ADULT n = 8 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 8 Sources: Page: p.6, 17 |
DLT: Skin rash, Hyperglycemia... Dose limiting toxicities: Skin rash (grade 3, 12.5%) Sources: Page: p.6, 17Hyperglycemia (grade 3, 12.5%) Mucosal inflammation (grade 3, 12.5%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Mucosal inflammation | grade 3, 25% DLT |
319 mg 1 times / week multiple, intravenous Highest studied dose Dose: 319 mg, 1 times / week Route: intravenous Route: multiple Dose: 319 mg, 1 times / week Sources: Page: p.6, 17 |
unhealthy, ADULT n = 4 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 4 Sources: Page: p.6, 17 |
skin rash | grade 3, 25% DLT |
319 mg 1 times / week multiple, intravenous Highest studied dose Dose: 319 mg, 1 times / week Route: intravenous Route: multiple Dose: 319 mg, 1 times / week Sources: Page: p.6, 17 |
unhealthy, ADULT n = 4 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 4 Sources: Page: p.6, 17 |
ALT increased | 2.4% DLT |
154 mg 1 times / week multiple, intravenous MTD Dose: 154 mg, 1 times / week Route: intravenous Route: multiple Dose: 154 mg, 1 times / week Sources: Page: p.6, 17 |
unhealthy, ADULT n = 42 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 42 Sources: Page: p.6, 17 |
AST increased | 2.4% DLT |
154 mg 1 times / week multiple, intravenous MTD Dose: 154 mg, 1 times / week Route: intravenous Route: multiple Dose: 154 mg, 1 times / week Sources: Page: p.6, 17 |
unhealthy, ADULT n = 42 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 42 Sources: Page: p.6, 17 |
Mucosal inflammation | grade 3, 2.4% DLT, Disc. AE |
154 mg 1 times / week multiple, intravenous MTD Dose: 154 mg, 1 times / week Route: intravenous Route: multiple Dose: 154 mg, 1 times / week Sources: Page: p.6, 17 |
unhealthy, ADULT n = 42 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 42 Sources: Page: p.6, 17 |
ALT increased | grade 2, 14.3% | 222 mg 1 times / week multiple, intravenous Studied dose Dose: 222 mg, 1 times / week Route: intravenous Route: multiple Dose: 222 mg, 1 times / week Sources: Page: p.6, 17 |
unhealthy, ADULT n = 7 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 7 Sources: Page: p.6, 17 |
Inflammation of mout | grade 3, 14.3% | 222 mg 1 times / week multiple, intravenous Studied dose Dose: 222 mg, 1 times / week Route: intravenous Route: multiple Dose: 222 mg, 1 times / week Sources: Page: p.6, 17 |
unhealthy, ADULT n = 7 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 7 Sources: Page: p.6, 17 |
Mucosal inflammation | grade 3, 14.3% | 222 mg 1 times / week multiple, intravenous Studied dose Dose: 222 mg, 1 times / week Route: intravenous Route: multiple Dose: 222 mg, 1 times / week Sources: Page: p.6, 17 |
unhealthy, ADULT n = 7 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 7 Sources: Page: p.6, 17 |
Mucosal inflammation | grade 3, 42.9% DLT |
222 mg 1 times / week multiple, intravenous Studied dose Dose: 222 mg, 1 times / week Route: intravenous Route: multiple Dose: 222 mg, 1 times / week Sources: Page: p.6, 17 |
unhealthy, ADULT n = 7 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 7 Sources: Page: p.6, 17 |
Hyperglycemia | grade 3, 12.5% DLT |
266 mg 1 times / week multiple, intravenous Studied dose Dose: 266 mg, 1 times / week Route: intravenous Route: multiple Dose: 266 mg, 1 times / week Sources: Page: p.6, 17 |
unhealthy, ADULT n = 8 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 8 Sources: Page: p.6, 17 |
Mucosal inflammation | grade 3, 12.5% DLT |
266 mg 1 times / week multiple, intravenous Studied dose Dose: 266 mg, 1 times / week Route: intravenous Route: multiple Dose: 266 mg, 1 times / week Sources: Page: p.6, 17 |
unhealthy, ADULT n = 8 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 8 Sources: Page: p.6, 17 |
Skin rash | grade 3, 12.5% DLT |
266 mg 1 times / week multiple, intravenous Studied dose Dose: 266 mg, 1 times / week Route: intravenous Route: multiple Dose: 266 mg, 1 times / week Sources: Page: p.6, 17 |
unhealthy, ADULT n = 8 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 8 Sources: Page: p.6, 17 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01420081
154mg IV weekly
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21325073
In vitro, Gedatolisib potently inhibited class I PI3Ks (IC(50) vs. PI3K-α = 0.4 nmol/L), PI3K-α mutants, and mTOR. Gedatolisib inhibited growth of 50 diverse human tumor cell lines at IC(50) values of less than 100 nmol/L.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2152
Created by
admin on Sat Dec 16 17:56:11 GMT 2023 , Edited by admin on Sat Dec 16 17:56:11 GMT 2023
|
||
|
NCI_THESAURUS |
C129825
Created by
admin on Sat Dec 16 17:56:11 GMT 2023 , Edited by admin on Sat Dec 16 17:56:11 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C91732
Created by
admin on Sat Dec 16 17:56:11 GMT 2023 , Edited by admin on Sat Dec 16 17:56:11 GMT 2023
|
PRIMARY | |||
|
96265TNH2R
Created by
admin on Sat Dec 16 17:56:11 GMT 2023 , Edited by admin on Sat Dec 16 17:56:11 GMT 2023
|
PRIMARY | |||
|
44516953
Created by
admin on Sat Dec 16 17:56:11 GMT 2023 , Edited by admin on Sat Dec 16 17:56:11 GMT 2023
|
PRIMARY | |||
|
100000174860
Created by
admin on Sat Dec 16 17:56:11 GMT 2023 , Edited by admin on Sat Dec 16 17:56:11 GMT 2023
|
PRIMARY | |||
|
1197160-78-3
Created by
admin on Sat Dec 16 17:56:11 GMT 2023 , Edited by admin on Sat Dec 16 17:56:11 GMT 2023
|
PRIMARY | |||
|
9984
Created by
admin on Sat Dec 16 17:56:11 GMT 2023 , Edited by admin on Sat Dec 16 17:56:11 GMT 2023
|
PRIMARY | |||
|
DTXSID40152557
Created by
admin on Sat Dec 16 17:56:11 GMT 2023 , Edited by admin on Sat Dec 16 17:56:11 GMT 2023
|
PRIMARY | |||
|
CHEMBL592445
Created by
admin on Sat Dec 16 17:56:11 GMT 2023 , Edited by admin on Sat Dec 16 17:56:11 GMT 2023
|
PRIMARY | |||
|
DB11896
Created by
admin on Sat Dec 16 17:56:11 GMT 2023 , Edited by admin on Sat Dec 16 17:56:11 GMT 2023
|
PRIMARY | |||
|
AB-113
Created by
admin on Sat Dec 16 17:56:11 GMT 2023 , Edited by admin on Sat Dec 16 17:56:11 GMT 2023
|
PRIMARY | |||
|
Gedatolisib
Created by
admin on Sat Dec 16 17:56:11 GMT 2023 , Edited by admin on Sat Dec 16 17:56:11 GMT 2023
|
PRIMARY |
ACTIVE MOIETY